Disease-Toxicant Interactions in Parkinson's Disease Neuropathology

Gunnar F Kwakye1, Rachael A McMinimy2, Michael Aschner3

  • 1Department of Neuroscience, Oberlin College, 119 Woodland St., Room K232, Oberlin, OH, 44074, USA. Gunnar.Kwakye@oberlin.edu.

Neurochemical Research
|September 11, 2016
PubMed

Insights

Environmental factors and genetic mutations interact to cause Parkinson's disease (PD). Understanding these interactions is key to developing new treatments and therapies for PD and related disorders.

Area of Science:

  • Neuroscience
  • Genetics
  • Environmental Health

Background:

  • Parkinson's disease (PD) arises from complex genetic and environmental interactions.
  • Understanding these interactions is crucial for developing effective treatments and research paradigms.
  • Shared pathophysiological mechanisms link genetics and environmental exposures in disease etiology.

Purpose of the Study:

  • To provide an integrated review of disease-toxicant interactions in Parkinson's disease.
  • To examine how genetic mutations and environmental factors contribute to PD pathogenesis.
  • To discuss neuroprotective compounds and current therapeutic strategies for PD.

Main Methods:

  • Review of existing literature on genetic and environmental factors in PD.
  • Analysis of gene mutations (SNCA, parkin, LRRK2, DJ-1) and their interaction with toxicants.
  • Examination of the role of the ubiquitin proteasome system and environmental exposures.

Main Results:

  • Mutations in specific genes (SNCA, parkin, LRRK2, DJ-1) and ubiquitin proteasome system dysfunction contribute to PD.
  • Exposure to heavy metals, pesticides, and illicit drugs can exacerbate PD symptoms and PD-like disorders.
  • Environmental toxicants' mechanisms are critical for understanding PD neuropathology.

Conclusions:

  • Elucidating gene-environment interactions in PD pathogenesis is vital for developing effective treatments.
  • Environmental factors, while not primary causes, significantly influence PD progression.
  • Estrogen and other compounds show neuroprotective potential against PD.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
100
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
223
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K